# Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis

> **NCT01457924** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 232 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** Ofatumumab 3mg
- **DRUG:** Ofatumumab 30mg
- **DRUG:** Ofatumumab 60mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01457924
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-11-01
- **Primary completion:** 2013-08-23
- **Final completion:** 2015-06-10
- **Target enrollment:** 232 (ACTUAL)
- **Last updated:** 2018-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01457924

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01457924, "Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01457924. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*